Filing Flows › Industries › Health Care › Biological Products (except Diagnostic Substances)
Biological Products (except Diagnostic Substances) SIC 2836
90 companies filing with the SEC under SIC 2836. Median revenue growth +9% year on year in Q3 2026 (middle half -5% to +40%, 36 companies). The growth model expects the industry's combined revenue to grow +8% in Q3 2026. 27 customer or supplier links named in annual reports.
Money flow: where the industry's revenue goes
Drawn in the browser: an estimate of where the industry's revenue goes — what it buys from other industries, the pay that reaches households, taxes and profit — beside its filed cash flow, two tiers of suppliers and its capital spending by kind of asset.
Open the industry: growth distribution, money flow, network →
Who sells to whom
Customers and suppliers named in the companies' annual reports; the share is of the supplier's revenue.
- AMGN → MCK 34% of the supplier's revenue, $12.5B
- AMGN → COR 27% of the supplier's revenue, $9.9B
- GILD → Cardinal Health, Inc. (“Cardinal Health”) 29% of the supplier's revenue, $8.5B
- GILD → McKesson Corporation (“McKesson”) 24% of the supplier's revenue, $7.1B
- GILD → Cencora, Inc. (“Cencora”) 21% of the supplier's revenue, $6.2B
- AMGN → CAH 16% of the supplier's revenue, $5.9B
- EXEL → Affiliates of Cencora, Inc 22% of the supplier's revenue, $510M
- EXEL → Affiliates of McKesson Corporation 19% of the supplier's revenue, $441M
- EXEL → Affiliates of CVS Health Corporation 15% of the supplier's revenue, $348M
- EXEL → CAH 12% of the supplier's revenue, $278M
- MRNA → CAH 11% of the supplier's revenue, $214M
- EXEL → RPRX 3% of the supplier's revenue, $69.6M
- ADPT → Genentech Inc And Roche Group 17% of the supplier's revenue, $46.0M
- DTIL → Novartis Pharma AG 77% of the supplier's revenue, $26.4M
- CHRS → MCK 43% of the supplier's revenue, $18.1M
- PSNL → MRNA 22% of the supplier's revenue, $15.3M
- CHRS → COR 36% of the supplier's revenue, $15.2M
- DVLT → SCLX 26% of the supplier's revenue, $10.2M
- CHRS → CAH 20% of the supplier's revenue, $8.4M
- PFE → PLX
- VYGR → NBIX
- TMO → DNA
- CAH → SCLX
- AMD → RGNX
- TWST → GRAL
Growth model
Industry revenue, the same companies year on year; 80% ranges. Fitted on SEC filings and tested out of sample (how).
| Quarter | Growth Y/Y | Revenue | 80% range |
|---|---|---|---|
| Q3 2026 | +8.1% | $26.6B | $24.2B – $29.1B |
| Q4 2026 | +7.2% | $27.2B | $24.3B – $30.1B |
| Q1 2027 | +6.4% | $23.8B | $21.2B – $26.4B |
| Q2 2027 | +5.7% | $27.2B | $24.1B – $30.2B |
Capital spending and supply chain →
Companies
| Company | Quarterly revenue | Y/Y | Stage |
|---|---|---|---|
| AMGN Amgen | $10.4B | +8% | mature |
| GILD Gilead Sciences | $8.3B | +7% | mature |
| BIIB Biogen | $2.8B | +11% | transition |
| MRNA Moderna | $1.3B | +29% | reacceleration |
| NBIX Neurocrine Biosciences | $1.1B | +41% | expansion |
| EXEL Exelixis | $659M | +10% | transition |
| HALO Halozyme Therapeutics | $493M | +39% | deceleration |
| MGTX MeiraGTx Holdings | $321M | — | reacceleration |
| TECH Bio-Techne | $300M | +5% | mature |
| VIR Vir Biotechnology | $239M | — | expansion |
| RGEN Repligen | $209M | +11% | transition |
| RVMD Revolution Medicines | $198M | — | contraction |
| TARS Tarsus Pharmaceuticals | $195M | +64% | deceleration |
| BCRX Biocryst Pharmaceuticals | $180M | +13% | deceleration |
| ALEC Alector | $163M | 50× | reacceleration |
| ADMA Adma Biologics | $141M | +5% | mature |
| KRYS Krystal Biotech | $127M | +30% | transition |
| IOVA Iovance Biotherapeutics | $121M | +80% | expansion |
| TWST Twist Bioscience | $118M | — | transition |
| IPSC Century Therapeutics | $109M | — | expansion |
| IMCR Immunocore Holdings | $102M | -1% | mature |
| VISK Viskase Holdings | $95.3M | +5% | mature |
| VCEL Vericel | $85.4M | +26% | transition |
| ADPT Adaptive Biotechnologies | $83.9M | -11% | contraction |
| BDTX Black Diamond Therapeutics | $70.0M | — | — |
| NVAX Novavax | $68.3M | -3% | mature |
| KYMR Kymera Therapeutics | $65.0M | — | expansion |
| GLUE Monte Rosa Therapeutics | $54.4M | +326% | reacceleration |
| IBRX ImmunityBio | $51.2M | — | deceleration |
| AUTL Autolus Therapeutics | $45.7M | — | deceleration |
| AGEN Agenus | $31.5M | +4% | deceleration |
| DNA Ginkgo Bioworks Holdings | $20.2M | — | transition |
| MAZE Maze Therapeutics | $20.0M | — | — |
| PLX Protalix BioTherapeutics | $19.9M | — | deceleration |
| RXRX Recursion Pharmaceuticals | $18.6M | +258% | reacceleration |
| FENC Fennec Pharmaceuticals | $17.9M | — | expansion |
| DNLI Denali Therapeutics | $17.8M | — | contraction |
| PTHS Pelthos Therapeutics | $15.6M | — | — |
| CSBR Champions Oncology | $15.2M | — | mature |
| CHRS Coherus Oncology | $14.3M | — | deceleration |
| IVVD Invivyd | $14.3M | — | transition |
| CRSP Crispr Therapeutics AG | $12.7M | 14× | expansion |
| EDIT Editas Medicine | $11.9M | — | reacceleration |
| DTIL Precision Biosciences | $10.8M | — | expansion |
| VXRT Vaxart | $10.6M | -85% | contraction |
| STRO Sutro Biopharma | $9.8M | — | contraction |
| RGNX Regenxbio | $9.2M | -69% | contraction |
| CCCC C4 Therapeutics | $8.5M | -25% | contraction |
| BSEM BioStem Technologies | $7.9M | — | contraction |
| SCLX Scilex Holding | $7.6M | — | contraction |
| ACOG Alpha Cognition | $6.1M | — | expansion |
| TSHA Taysha Gene Therapies | $5.5M | — | expansion |
| SRZN Surrozen | $5.0M | — | expansion |
| ALLO Allogene Therapeutics | $4.6M | — | contraction |
| VYGR Voyager Therapeutics | $4.0M | -70% | contraction |
| FDMT 4D Molecular Therapeutics | $3.8M | — | expansion |
| LENZ Lenz Therapeutics | $3.4M | -73% | contraction |
| ALGS Aligos Therapeutics | $2.8M | +282% | deceleration |
| XFOR X4 Pharmaceuticals | $2.8M | +79% | expansion |
| ELUT Elutia | $2.4M | — | contraction |
Growth from positive, comparable quarterly revenue as filed; industries are SEC Standard Industrial Classification codes. Data Nov 8, 2026.